Description: Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Home Page: www.replimune.com
REPL Technical Analysis
500 Unicorn Park Drive
Woburn,
MA
01801
United States
Phone:
781 222 9600
Officers
| Name | Title |
|---|---|
| Mr. Philip Astley-Sparke FSA | CEO & Director |
| Dr. Robert Coffin Ph.D. | Founder, Pres, Chief R&D Officer and Director |
| Ms. Tanya N. Lewis M.S. | Chief Devel. Operations Officer |
| Mr. Sushil Patel Ph.D. | Chief Commercial Officer |
| Ms. Jean M. Franchi | Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer |
| Dr. Colin A. Love Ph.D. | Chief Operating Officer |
| Dr. Pamela Esposito Ph.D. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.6145 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-07-20 |
| Fiscal Year End: | March |
| Full Time Employees: | 206 |